LIAISON QuantiFERON - TB Gold Plus and LIAISON XL Control QuantiFERON-TB Gold Plus
DiaSorin, Inc. · Decision date Aug 21, 2025
What did the FDA decide?
FDA records P180047/S038 as a supplement to PMA P180047, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 21, 2025.
FDA approval order statement
a manufacturing process transfer from one DiaSorin facility to another
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Aug 21, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P180047/S038
- Regulatory pathway
- PMA supplement
- Applicant
- DiaSorin, Inc.
- Product code
- NCD
- Decision code
- OK30
- Decision date
- Aug 21, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS.
- Applicant
- DiaSorin, Inc.
- Product code
- NCD
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P180047. Subsequent supplements may change the device or its indications.
FDA decision timeline
P180047 · Original PMA
LIAISON QuantiFERON - TB Gold Plus, LIAISON Control QuantiFERON - TB Gold Plus and LIAISON QuantiFERON Software
P180047/S038 received
Application receipt date recorded by FDA.
P180047/S038 · FDA decision
30-Day Notice
P180047/S040 · Related supplement
LIAISON QuantiFERON - TB Gold Plus and LIAISON Control QuantiFERON-TBGold Plus
P180047/S037 · Related supplement
LIAISON QuantiFERON - TB Gold Plus and LIAISON XL Control QuantiFERON-TB Gold Plus
P180047/S041 · Related supplement
LIAISON QuantiFERON-TB Gold Plus and LIAISON Control QuantiFERON-TB Gold Plus
P180047/S039 · Related supplement
LIAISON QuantiFERON TB Gold Plus II; LIAISON Control QuantiFERON TB Gold Plus II
P180047/S044 · Related supplement
LIAISON QuantiFERON - TB Gold Plus, LIAISON Control QuantiFERON - TB Gold Plus and LIAISON QuantiFERON Software
P180047/S043 · Related supplement
LIAISON QuantiFERON-TB Gold Plus; LIAISON XL Control QuantiFERON-TB Gold Plus; LIAISON QuantiFERON-TB Gold Plus II; LIAI
P180047/S045 · Related supplement
LIAISON QuantiFERON-TB Gold III; LIAISON Control QuantiFERON-TB Gold III; LIAISON QuantiFERON-TB Gold Plus II; LIAISON C
P180047/S046 · Related supplement
LIAISON QuantiFERON-TB Gold Plus II.
Timeline entries are records held by MedtechLedger for P180047. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180047
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| DiaSorin, Inc. | PMA approval | Nov 26, 2019 | FDA | |
| DiaSorin, Inc. | PMA supplement | Aug 28, 2025 | FDA | |
| DiaSorin, Inc. | PMA supplement | Oct 10, 2025 | FDA | |
| DiaSorin, Inc. | PMA supplement | Dec 19, 2025 | FDA | |
| DiaSorin, Inc. | PMA supplement | Jan 26, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | May 26, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | Aug 27, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | Aug 27, 2026 | FDA | |
LIAISON QuantiFERON-TB Gold Plus II.P180047/S046 | DiaSorin, Inc. | PMA supplement | Sep 24, 2026 | FDA |
Explore the linked device profile
Other records with product code NCD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
QuantiFERON-TB Gold Plus TestP010033/S053 | Qiagen | PMA supplement | Oct 14, 2026 | FDA |
| Qiagen | PMA supplement | Jan 23, 2026 | FDA | |
QuantiFERON-TB Gold Plus TestP010033/S051 | Qiagen | PMA supplement | Nov 21, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
DiaSorin, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1951 Northwestern Ave., Stillwater, MN, 55082
Sources and methodology
- Original FDA record: P180047/S038
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





